© Copyright 2012 Chemical Biology Ventures Limited. All Rights Reserved. Registered in England & Wales number 7968150. Registered office: 30 Upper High Street, Thame, Oxfordshire, OX9 3EZ. Address for correspondence: 123 Alexander Close, Abingdon, Oxfordshire, OX14 1XD
Tel: +44 (0) 1235 532481
Mob: 07836 554231
Email: [email protected]
CBV has extensive experience in anti-infective R&D including viral & bacterial disease. Lloyd Czaplewski has a strong track record in generating anti-infective IP & in advancing projects through preclinical development . He is an international opinion leader working with venture capital, research councils & charities to build the case for greater investment in antibacterial translational research.
Trkola, A., Gordon, C., Matthews, J., Maxwell, E., Ketas, T., Czaplewski, L., Proudfoot, A.E.I., and Moore, J. The CC chemokine RANTES increases the attachment of human immunodeficiency virus type 1 to target cells via glycosaminoglycans, and also activates a signal transduction pathway that enhances viral infectivity. J. Virology 73, 6370-6379 1999.
Chopra I., Schofield C., Everett M., O’Neill A., Miller K., Wilcox M., Frere J-M., Dawson M., Czaplewski L., Urleb U., Courvalin P. Treatment of health-care-associated infections caused by Gram-negative bacteria: a consensus statement. Lancet Infect. Dis 8: 133-139, 2008.
Haydon DJ, Stokes NR, Ure R, Galbraith G, Bennett JM, Brown D, Baker PJ, Barynin VV, Rice DW, Sedelnikova SE, Heal JR, Sheridan JM, Aiwale ST, Chauhan PK, Srivastava A, Taneja A, Collins I, Errington J, Czaplewski LG. A novel inhibitor of FtsZ with potent and selective anti-staphylococcal activity. Science 321, 1673-167